Lenz Robert A. — SEC Form 4 filings
SEC reporting owner CIK 1992908. 9 Form 4 filings on record with FilingPulse; latest filed 2026-08-25.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-16 to 2026-08-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 4 filings — 93,849 shares, $1,086,985 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 32,948 shares @ $11.43 ($376,665) in Neumora Therapeutics, Inc., filed 2024-09-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | Head of R&D | 6 | — | 6 legs · 93,849 sh · $1,086,985 | 6 |
| LB PHARMACEUTICALS INC (LBRX) | Director | 2 | — | — | 2 |
| NovaBridge Biosciences (NBP) | Director | 1 | — | — | 2 |
Form 4 filings — Lenz Robert A.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-25 | 4 | NovaBridge Biosciences (NBP) | Option exercise (M): 17,218 · Option exercise (M): 7,486 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 5,614 @ $1.67 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 502,934 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Grant/award (A): 502,934 (derivative) · Grant/award (A): 100,000 (derivative) | EDGAR |
| 2024-10-11 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 5,563 @ $15.01 · Sale (S): 8,260 @ $15.09 | EDGAR |
| 2024-09-19 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 30,788 @ $11.81 · Sale (S): 10,676 @ $12.09 | EDGAR |
| 2024-09-16 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 32,948 @ $11.43 | EDGAR |
| 2024-02-16 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1992908 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →